Papp L Roy & Associates acquired a new position in Zoetis Inc (NYSE:ZTS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,640 shares of the company’s stock, valued at approximately $204,000.
A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. Nuveen Asset Management LLC lifted its holdings in Zoetis by 40,874.9% in the second quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock worth $803,376,000 after buying an additional 7,061,550 shares during the period. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in Zoetis in the second quarter worth about $133,113,000. Bank of New York Mellon Corp lifted its holdings in Zoetis by 9.5% in the second quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock worth $501,654,000 after buying an additional 383,799 shares during the period. Vanguard Group Inc. lifted its holdings in Zoetis by 1.0% in the second quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock worth $4,172,526,000 after buying an additional 346,167 shares during the period. Finally, Natixis lifted its holdings in Zoetis by 147.1% in the second quarter. Natixis now owns 547,078 shares of the company’s stock worth $62,088,000 after buying an additional 325,661 shares during the period. Institutional investors and hedge funds own 89.95% of the company’s stock.
In related news, EVP Clinton A. Jr. Lewis sold 6,123 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $128.62, for a total value of $787,540.26. Following the completion of the transaction, the executive vice president now directly owns 39,141 shares in the company, valued at approximately $5,034,315.42. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kristin C. Peck sold 11,500 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the completion of the transaction, the executive vice president now owns 48,877 shares of the company’s stock, valued at $6,022,623.94. The disclosure for this sale can be found here. Insiders have sold 34,332 shares of company stock valued at $4,258,182 over the last quarter. Company insiders own 0.29% of the company’s stock.
Shares of ZTS stock traded down $3.17 during trading hours on Friday, hitting $117.86. 3,757,845 shares of the company’s stock traded hands, compared to its average volume of 2,125,332. The stock’s fifty day simple moving average is $125.46 and its two-hundred day simple moving average is $116.48. Zoetis Inc has a 12-month low of $78.90 and a 12-month high of $130.20. The stock has a market cap of $57.43 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 2.98 and a beta of 0.88. The company has a quick ratio of 2.87, a current ratio of 4.17 and a debt-to-equity ratio of 2.74.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.06. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.58 billion. During the same period last year, the business earned $0.83 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Tuesday, October 22nd will be issued a dividend of $0.164 per share. The ex-dividend date of this dividend is Monday, October 21st. This represents a $0.66 annualized dividend and a dividend yield of 0.56%. Zoetis’s payout ratio is 21.09%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: What are the disadvantages of after-hours trading?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.